Management ChangeMay 19, 2026, 04:53 PM
Aura Biosciences Appoints Natalie Holles as New CEO & President
AI Summary
Aura Biosciences announced the appointment of Natalie Holles as its new Chief Executive Officer and President, effective May 19, 2026. In connection with her appointment, Ms. Holles received inducement equity awards, including non-qualified stock options for 2,169,103 shares at an exercise price of $7.39, restricted stock units for 600,118 shares, and performance-based restricted stock units for 553,844 shares. These awards are subject to specific time-based and performance-based vesting conditions.
Key Highlights
- Natalie Holles appointed new CEO and President of Aura Biosciences on May 19, 2026.
- Granted non-qualified stock options for 2,169,103 shares at $7.39 exercise price.
- Received Restricted Stock Units (RSUs) for 600,118 shares.
- Received Performance-Based Restricted Stock Units (PRSUs) for 553,844 shares.
- Option Award vests 25% on April 30, 2027, then monthly over 36 months.
- RSUs vest 25% on April 15, 2027, and annually for three subsequent years.
- PRSUs vest in four annual installments, subject to time and performance conditions.
Price Impact
More from AURA